The group�s principle activity is to develop therapeutic and vaccine technologies to reduce morbidity and mortality caused by viral diseases. The group�s technologies include Antiviral Immune Modulating therapy, thermal stabilizers, genetic adjuvants, and transition state vaccines. The group operates from United States.